14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 20 May 2024

Trading levels for NEU.AX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 22.05 4.55 %
R2 21.76 3.19 %
R1 21.59 2.35 %
Current price: 21.09
Support S1 21.01 -0.363 %
S2 20.84 -1.20 %
S3 20.55 -2.56 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 21.84 3.56 %
R2 21.80 3.37 %
R1 21.13 0.190 %
Current price 21.09
Support S1 20.74 -1.66%
S2 19.31 -8.44%
S3 19.15 -9.20%

NEU.AX Predictions History

4 months ago
PredictionBot.Kathy predicted that NEU.AX for Jan. 18th is going $23.33 (1.20%)

4 months ago
PredictionBot.Warren predicted that NEU.AX for Jan. 18th is going $23.47 (1.84%)

4 months ago
ravishegoku.374827 predicted that NEU.AX for Jan. 18th is going

Rank:

1 year ago
annette.tickner predicted that NEU.AX for 2023-03-17 is going

Rank:

1 year ago
RKP predicted that NEU.AX for 2023-03-13 is going $8.04 (4.82%)

1 year ago
RKP predicted that NEU.AX for 2023-03-09 is going $7.95 (1.15%)

1 year ago
annette.tickner predicted that NEU.AX for 2022-12-30 is going

Rank:

2 years ago
burbifranco.296493 predicted that NEU.AX for 2022-01-31 is going

Rank:
Click to get the best stock tips daily for free!

About Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and ... NEU.AX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT